CA3023305C - COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES - Google Patents

COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES

Info

Publication number
CA3023305C
CA3023305C CA3023305A CA3023305A CA3023305C CA 3023305 C CA3023305 C CA 3023305C CA 3023305 A CA3023305 A CA 3023305A CA 3023305 A CA3023305 A CA 3023305A CA 3023305 C CA3023305 C CA 3023305C
Authority
CA
Canada
Prior art keywords
valerian
composition
related methods
polymer
acidifying agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3023305A
Other languages
English (en)
French (fr)
Other versions
CA3023305A1 (en
Inventor
Syed M Shah
Christopher Diorio
Daniel Hassan
Fred Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Physicians Seal LLC
Original Assignee
Physicians Seal LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal LLC filed Critical Physicians Seal LLC
Publication of CA3023305A1 publication Critical patent/CA3023305A1/en
Application granted granted Critical
Publication of CA3023305C publication Critical patent/CA3023305C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3023305A 2016-05-06 2017-05-04 COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES Active CA3023305C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332728P 2016-05-06 2016-05-06
US62/332,728 2016-05-06
PCT/US2017/031046 WO2017192843A1 (en) 2016-05-06 2017-05-04 Valerian composition and related methods

Publications (2)

Publication Number Publication Date
CA3023305A1 CA3023305A1 (en) 2017-11-09
CA3023305C true CA3023305C (en) 2024-07-02

Family

ID=60203773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023305A Active CA3023305C (en) 2016-05-06 2017-05-04 COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES

Country Status (10)

Country Link
US (4) US10342873B2 (enExample)
EP (1) EP3452020A4 (enExample)
JP (2) JP7576905B2 (enExample)
KR (1) KR20190008265A (enExample)
CN (2) CN109310638A (enExample)
AU (1) AU2017260019A1 (enExample)
CA (1) CA3023305C (enExample)
MX (1) MX2018013569A (enExample)
RU (1) RU2018142019A (enExample)
WO (1) WO2017192843A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723862B2 (en) * 2020-01-17 2023-08-15 Societe Des Produits Nestle S.A. Dosage form with sustained release melatonin pellets
IT202200013576A1 (it) * 2022-06-27 2023-12-27 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato a rilascio differenziato di melatonina e principi attivi

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699075A1 (fr) * 1992-12-11 1994-06-17 Rech Sarl Ab Préparation médicinale à libération programmable dans le temps notamment à base de plantes.
FR2713636B1 (fr) 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2727315A1 (fr) 1994-11-30 1996-05-31 Cooperative Agricole Laitiere Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
JP2003505426A (ja) 1999-07-21 2003-02-12 アンシル ファーマシューティカルズ，インコーポレイテッド バレリアン根の抽出方法
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US20050220869A1 (en) * 2001-12-20 2005-10-06 Federico Stroppolo Particulate compositions
WO2005097101A1 (ja) * 2004-04-06 2005-10-20 Taiyokagaku Co., Ltd. 睡眠改善用組成物
JP5154924B2 (ja) 2004-05-11 2013-02-27 エガレット エイ／エス ジェランガムを含む膨張可能な投与形態
EP1824450B1 (en) 2004-10-11 2012-11-14 Nasaleze Patents Limited Compositions for intranasal administration
AU2006260201B2 (en) 2005-06-22 2011-10-20 Takeda Pharmaceutical Company Limited Tablet containing hardly soluble active ingredient
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
CN1850212A (zh) * 2006-02-28 2006-10-25 潮州市强基制药厂 一种缬草油液体硬胶囊及其制备方法
WO2008037707A2 (de) 2006-09-27 2008-04-03 Finzelberg Gmbh & Co. Kg Baldrian-extraktzubereitung
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20090197974A1 (en) * 2008-02-05 2009-08-06 Khaleeq Ahmed Natural dietary supplement tablet
WO2010084182A1 (en) 2009-01-23 2010-07-29 Universität Wien Methods for making valerenic acid derivatives and their use
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
CN102370833B (zh) * 2010-08-17 2014-03-26 北京亚东生物制药有限公司 一种解表祛暑的泡腾剂及其制备方法和用途
CN102058630B (zh) * 2010-12-16 2014-03-19 苏州大学 一种镇静安神的缬草制剂及其制备方法
CN102247443A (zh) * 2010-12-23 2011-11-23 祝凤仪 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法
CN103429223A (zh) 2011-01-17 2013-12-04 武田药品工业株式会社 口腔分散片
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
CN102114060B (zh) * 2011-02-22 2012-12-12 都晓伟 黑水缬草提取物及其制备方法和应用
JP2013053144A (ja) * 2011-08-09 2013-03-21 Daiichi Sankyo Healthcare Co Ltd 鎮静剤組成物
US20130116215A1 (en) * 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
EP2806756B1 (en) 2012-01-26 2021-10-27 Incredible Foods, Inc. Enclosing materials in natural transport systems
EP4502609A3 (en) 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
WO2014083438A2 (en) 2012-11-09 2014-06-05 Abattis Bioceuticals Corp Nitric oxide increasing nutritional supplements and methods
US20140271890A1 (en) 2013-03-14 2014-09-18 Thaer Ahmad Controlled-release pharmaceutical composition
HUE042996T2 (hu) 2013-04-23 2019-07-29 Zx Pharma Llc Bélben oldódó bevonatú, fehérjetartalmú alapbevonattal ellátott, több részecskét tartalmazó készítmény
PL231923B1 (pl) 2013-10-28 2019-04-30 Proteon Pharmaceuticals Spolka Akcyjna Sposób enkapsulacji materiału zawierającego bakteriofagi, otrzymywana nim mikrokapsułka oraz jej zastosowania
RU2535020C1 (ru) 2014-01-23 2014-12-10 Карпов Алексей Николаевич Фармацевтическая композиция седативного и спазмолитического действия
EP3632416A1 (en) * 2014-02-06 2020-04-08 Lan Bo Chen Composition and method for aiding sleep
CA2948070C (en) * 2014-05-05 2024-02-13 Boehringer Ingelheim International Gmbh Fast dissolving granulate
HUE031669T2 (en) 2014-07-14 2017-07-28 Dr Willmar Schwabe Gmbh & Co Kg Cataract extract and lavender oil combination for sleeping disorders

Also Published As

Publication number Publication date
US20210401990A1 (en) 2021-12-30
KR20190008265A (ko) 2019-01-23
US20190321475A1 (en) 2019-10-24
BR112018072795A2 (pt) 2019-04-30
CA3023305A1 (en) 2017-11-09
EP3452020A4 (en) 2020-02-19
US20190328881A1 (en) 2019-10-31
US11141485B2 (en) 2021-10-12
US11141484B2 (en) 2021-10-12
CN117482062A (zh) 2024-02-02
RU2018142019A3 (enExample) 2020-09-16
RU2018142019A (ru) 2020-06-08
WO2017192843A1 (en) 2017-11-09
CN109310638A (zh) 2019-02-05
JP2019514977A (ja) 2019-06-06
US11701425B2 (en) 2023-07-18
US10342873B2 (en) 2019-07-09
AU2017260019A1 (en) 2018-11-22
MX2018013569A (es) 2019-03-14
JP2022116251A (ja) 2022-08-09
US20170319697A1 (en) 2017-11-09
EP3452020A1 (en) 2019-03-13
JP7577090B2 (ja) 2024-11-01
JP7576905B2 (ja) 2024-11-01

Similar Documents

Publication Publication Date Title
EP3386484A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPEUTIC ACTIVITIES
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
CL2016002308A1 (es) Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer
MA43347B1 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
MX390145B (es) Formulaciones para la administracion de eflornitina
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12017502081A1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
EP3452441A4 (en) ALPHA-TRUXILLINIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
CA3023305C (en) COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES
PH12018502139A1 (en) Phosphaplatin liquid formulations
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
TW201613926A (en) Inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504